The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...

The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Big pharmaceutical companies are seeing Chinese biotech as the disruptors. Read more at straitstimes.com. Read more at straitstimes.com.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

US factory activity contracted in May for a third consecutive month and a gauge of imports fell to a 16-year low as firms ...